TY - JOUR
T1 - Clinical application of transepithelial potential difference measurements in cystic fibrosis
AU - Sauder, Russell A.
AU - Chesrown, Sarah E.
AU - Loughlin, Gerald M.
N1 - Funding Information:
Supported by American Lung Association of Florida, Pediatric Pulmonary Center Grant MCJ-2013, and New Investigation Research Award HL-26952-03 from the National Heart, Lung, and Blood Institute. Presented in part at the Annual Meeting of the Cystic Fibrosis Club, Anaheim, Calif., 1984. Submitted for publication Feb. 25, 1987; accepted May 5, 1987. Reprint requests: Gerald M. Loughlin, MD, The Johns Hopkins Hospital, Department of Pediatrics, CMSC 141, 600 N. Wolfe St., Baltimore, MD 21205.
PY - 1987/9
Y1 - 1987/9
N2 - We studied transepithelial potential difference (PD) in normal persons, patients with chronic disease, and patients with cystic fibrosis (CF), using the technique described by knowles and co-workers. A maximal PD value (PDmax) and an average PD value (PDmean) were determined for each study of the nasal respiratory epithelium. The volfage response to superfusion of 10-4 mol/L amiloride onto nasal mucosa was noted. The PD of the palm, wrist, and between two fingertips was also measured. Nasal PDmax and PDmean of the CF group were more negative than the control (P<0.01) and chronic disease groups (P<0.01). After application of amiloride, the voltage change in nasal PD was greater in the CF group than in the non-CF control groups (P<0.01). There were no clinically significant differences in the PD of the palm, wrist, or fingertips of the three groups. These data confirm the observation that patients with CF have hyperpolarized nasal epithelia that demonstrate greater change in response to amiloride than that in non-CF controls. These results indicate a possible role for the use of in vivo nasal PD measurements as a diagnostic test for cystic fibrosis.
AB - We studied transepithelial potential difference (PD) in normal persons, patients with chronic disease, and patients with cystic fibrosis (CF), using the technique described by knowles and co-workers. A maximal PD value (PDmax) and an average PD value (PDmean) were determined for each study of the nasal respiratory epithelium. The volfage response to superfusion of 10-4 mol/L amiloride onto nasal mucosa was noted. The PD of the palm, wrist, and between two fingertips was also measured. Nasal PDmax and PDmean of the CF group were more negative than the control (P<0.01) and chronic disease groups (P<0.01). After application of amiloride, the voltage change in nasal PD was greater in the CF group than in the non-CF control groups (P<0.01). There were no clinically significant differences in the PD of the palm, wrist, or fingertips of the three groups. These data confirm the observation that patients with CF have hyperpolarized nasal epithelia that demonstrate greater change in response to amiloride than that in non-CF controls. These results indicate a possible role for the use of in vivo nasal PD measurements as a diagnostic test for cystic fibrosis.
UR - http://www.scopus.com/inward/record.url?scp=0023641255&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0023641255&partnerID=8YFLogxK
U2 - 10.1016/S0022-3476(87)80453-5
DO - 10.1016/S0022-3476(87)80453-5
M3 - Article
C2 - 2442338
AN - SCOPUS:0023641255
SN - 0022-3476
VL - 111
SP - 353
EP - 358
JO - Journal of Pediatrics
JF - Journal of Pediatrics
IS - 3
ER -